What is the recommended evaluation and management protocol for gender dysphoria in the NAC OSCE in Canada?

Evaluation and Management of Gender Dysphoria for NAC OSCE Canada

For the NAC OSCE, approach gender dysphoria evaluation by establishing the patient's gender identity, assessing psychological distress, screening for mental health comorbidities (particularly depression, anxiety, and suicidality), and determining readiness for gender-affirming interventions while demonstrating cultural humility and using patient-preferred names and pronouns throughout the encounter.

Key Terminology and Definitions

Understanding precise terminology is critical for the OSCE 1:

• Gender dysphoria: Psychological distress from incongruence between gender identity and sex assigned at birth—distinct from gender identity itself, which is not a mental health condition
• Gender identity: Internal self-perception along a spectrum (male, female, both, neither)
• Gender expression: External presentation through appearance, clothing, voice, behaviors
• Sexual orientation: Separate construct from gender identity—ask patients directly about their terminology preferences

Critical OSCE pitfall: Gender dysphoria will be replaced by "gender incongruence" in the next ICD edition, but the term persists for billing purposes 2.

Essential History Components

Gender-Specific Questions

Ask directly and respectfully 1:

• Preferred name and pronouns (use these consistently throughout)
• When did you first become aware of your gender identity? (Most youth are gender-aware before age 12 3)
• How do you currently express your gender in daily life? (Note: Only 58% of transfeminine youth live full-time in their gender vs. 90% of transmasculine 3)
• What aspects of your body cause you distress?
• What are your goals for gender affirmation?

Mental Health Screening (High Priority)

This is critical—TGD youth have markedly elevated mental health risks 1, 3:

• Depression screening: 21% of transmasculine youth report depressive symptoms 3
• Anxiety screening: 66% of transmasculine and 33% of transfeminine youth report anxiety 3
• Suicidality assessment: 34.5% report past-year ideation, 16.8% report attempts 3—this must be explicitly assessed
• Screen for trauma history given high rates of discrimination and violence

Social Support Assessment

Evaluate 3:

• Parental/family support: 62% report strong parental gender support; parents are most common support persons (92%)
• School environment and peer relationships
• External gender-related stressors: Two-thirds of families report these 3
• Socioeconomic factors: 27% are low-income, 19% Indigenous, with higher rates of financial disadvantage 3

Physical Examination Considerations

Use patient-preferred anatomical terminology 1—ask first: "What terms would you like me to use when discussing your body?"

For youth considering medical intervention:

• Tanner staging to assess pubertal development
• Baseline vital signs and BMI
• Document baseline physical characteristics relevant to treatment goals

Differential Considerations

Distinguish gender dysphoria from 4:

• Psychiatric disorders (body dysmorphic disorder, psychosis)
• Neurodevelopmental conditions (though these can co-exist)
• Social influences in rapid-onset presentations (particularly in adolescent-onset natal females 5)

Management Framework

Psychosocial Support (First-Line for All)

Gender affirmation reduces psychological distress and suicidality 1:

• Affirm patient's gender identity and expression
• Connect with transgender-competent mental health professionals
• Facilitate social transition (name, pronouns, presentation) as appropriate
• Address family dynamics and school environment

Medical Interventions (Referral-Based)

For the OSCE, demonstrate knowledge of the pathway without prescribing 2, 6, 3, 4:

Puberty Suppression (GnRH Analogs)

• Indication: Pubertal or early post-pubertal youth with persistent gender dysphoria
• Common agents: Leuprolide acetate (depot), triptorelin 6, 3
• Median age of initiation: Around 13-14 years in Canadian cohorts 3
• Key point: 32% of Canadian youth receive GnRH analog treatment 6
• Evidence quality: Very low certainty regarding effects 7—acknowledge this uncertainty

Gender-Affirming Hormone Therapy (GAHT)

For transmasculine patients 2, 6:

• Testosterone injections typically started at median age 17.3 years (range 13.7-19.8)
• Effects: Increased muscle mass (15% thigh volume, 6% quadriceps CSA), 12% strength increase

For transfeminine patients 2, 6:

• Estrogen (oral, transdermal, or parenteral) plus antiandrogen (spironolactone, cyproterone acetate)
• Median initiation age 17.9 years (range 13.3-22.3)
• Effects: Decreased muscle volume (5%), decreased lean body mass (3-5%), breast development over 3+ years, decreased hemoglobin

Safety note: No severe complications noted in Canadian cohort; 3 patients temporarily stopped due to psychiatric comorbidities or androgenic alopecia 6

Surgical Interventions

Not typically discussed in initial OSCE encounters—focus on establishing rapport and initial assessment 4

OSCE Communication Priorities

Demonstrate cultural humility and trauma-informed care 1:

1. Use patient's preferred name and pronouns consistently
2. Normalize the conversation: "Thank you for sharing this with me. I want to make sure I provide you with the best care possible."
3. Acknowledge discrimination: "I know many transgender people have had negative experiences with healthcare. I'm committed to providing affirming care."
4. Assess safety: Both mental health (suicidality) and social (family, school, community)
5. Explain next steps clearly: Referral to specialized gender clinic, mental health support, timeline expectations

Canadian Context Specifics

For NAC OSCE, be aware 3:

• 10 specialized gender clinics exist across Canada
• Median age at first referral visit: 14-15 years (69%)
• Most youth have already seen family physicians (68.5%) before specialty referral
• 62.4% receive hormonal suppression or GAHT at first clinic visit
• Higher representation of Indigenous youth (18.8%) and immigrant families (25.7%)

Critical Pitfalls to Avoid

1. Never pathologize gender identity itself—only the distress (dysphoria) may require treatment 2, 1
2. Don't assume gender expression equals gender identity—ask directly 1
3. Don't conflate sexual orientation with gender identity—these are separate 1
4. Avoid making assumptions about anatomy or surgical history—use patient's terminology 1
5. Don't minimize mental health screening—suicide risk is substantially elevated 3
6. Acknowledge evidence limitations honestly—certainty about intervention effects remains low 7, 8

Documentation

In the OSCE, verbalize that you would document 1:

• Patient's preferred name and pronouns prominently
• Gender identity and expression separately
• Mental health screening results with specific suicide risk assessment
• Support systems and stressors
• Patient's goals for gender affirmation
• Referrals initiated